Physician profile
Diane J Sutter
NPI 1447291703
$94,773.60
in general payments reported to CMS, 2019-2025
59 companies · $9,388 in 2025
The $9,388 reported for 2025 was more than what 95% of Gynecology providers received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $2,047 · 2021: $5,185 · 2022: $20K · 2023: $36K · 2024: $10K · 2025: $9,388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $43K · Food and Beverage: $8,727 · Travel and Lodging: $4,381 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $42,605.00 |
| Food and Beverage | $8,726.96 |
| Travel and Lodging | $4,380.74 |
| Education | $169.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $38,714.62 | 2019-2025 | Veozah, Xospata, Myrbetriq |
| Pfizer INC. | $15,720.70 | 2019-2025 | |
| Abbvie INC. | $10,110.57 | 2019-2025 | Qulipta, Orilissa, Ubrelvy |
| Myovant Sciences INC. | $7,628.64 | 2021-2022 | |
| Amag Pharmaceuticals, INC. | $5,903.11 | 2019 | |
| Therapeuticsmd, INC. | $3,899.71 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $2,111.79 | 2023-2025 | Myfembree, Gemtesa |
| Mayne Pharma Commercial LLC | $1,452.03 | 2021-2025 | Annovera, Nextstellis, Bijuva |
| Amgen INC. | $1,410.93 | 2019-2024 | Evenity, Prolia, Otezla |
| Novo Nordisk INC | $1,199.98 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Axsome Therapeutics, INC. | $648.37 | 2022-2025 | Auvelity, Symbravo |
| Radius Health, INC. | $482.11 | 2019-2025 | Tymlos |
| Lilly USA, LLC | $477.11 | 2019-2024 | Zepbound, Jardiance, Emgality |
| Avion Pharmaceuticals | $386.67 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $373.12 | 2019-2025 | Trintellix |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Sutter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.